Medtronic’s IN.PACT AV Access trial meets effectiveness endpoints
Category: #health  By Mateen Dalal  Date: 2019-09-09
  • share
  • Twitter
  • Facebook
  • LinkedIn

Medtronic’s IN.PACT AV Access trial meets effectiveness endpoints

IN.PACT AV DCB showed encouraging results in the treatment of AV Fistulae Lesions in Renal Disease Patients at its last stage.

Medtronic plc, one of the world’s biggest medical device companies, has recently announced outcomes from its IN.PACT AV Access clinical trials assessing the PTA (percutaneous transluminal angioplasty) against the IN.PACT™ AV™ DCB (drug-coated balloon) in subjects with non-stented or de novo restenotic AV (arteriovenous) fistulae lesions.

Reportedly, the trials recently achieved its effectiveness endpoints and primary safety, presenting the data at the CIRSE (Cardiovascular and Interventional Radiology Society of Europe) annual meeting in Spain.

Speaking on the move, Andrew Holden, M.D., Associate Professor of Radiology at Auckland University and Director of Interventional Radiology at Auckland Hospital, said that limiting the frequency and maintaining patency of reinterventions demanded AV access sites to properly function remains the major treatment challenges for physicians doctoring AV fistulae lesions.

He said that these results show the potential of IN.PACT AV DCB in addressing these crucial issues and in improving the quality of life of patients going through dialysis.

For the uninitiated, AV fistulae, also known as AV access sites, was developed and used to provide hemodialysis to patients with ESRD (end-stage renal disease). As time passes, vessel restenosis restricts the capability to use AV fistulae efficiently. Hence, in order to rebuild function, patients frequently go through several AV fistula maintenance procedures each year. 

However, the need for repeated reinterventions can lead to a major disruption in serious hemodialysis care and would raise the costs of the healthcare system. Additionally, drug-coated balloons could extend the time between reinterventions by sustaining AV access site patency, increasing the patient’s constant access to dialysis care.

According to sources, the primary effectiveness endpoint reduced CD-TLR (clinically-driven target lesion revascularization). Moreover, additional endpoints involved collective target lesion revascularization, a number of interventions needed to sustain target lesion patency and access circuit primary patency.

Source Credit: http://newsroom.medtronic.com/news-releases/news-release-details/inpact-av-access-trial-meets-primary-safety-and-effectiveness

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

FDA warns Dollar Tree regarding the sale of imported adulterated drugs
FDA warns Dollar Tree regarding the sale of imported adulterated drugs
By Mateen Dalal

FDA’s new warning letter is asking Dollar Tree to ensure the company does not import adulterated medicines   Manufacturers mentioned in the letter include Hangzhou Zhongbo and Shanghai Weierya Daily Chemicals Reports confirm that the...

Cellectis reveals POC for smart T-cells that recognize tumors
Cellectis reveals POC for smart T-cells that recognize tumors
By Mateen Dalal

Cellectis, a French biopharmaceutical company that aims to innovate immunotherapies based on gene-edited allogeneic CAR T-cells, recently revealed a report issued in Nature Communications that explains a proof-of-concept (POC) for cell path...

Arranta Bio acquires Captozyme to accelerate microbiome development
Arranta Bio acquires Captozyme to accelerate microbiome development
By Mateen Dalal

Arranta has established a Center of Excellence for microbiome development   The acquisition will help quicken the delivery of LBPs for clients worldwide Arranta Bio, a leading Contract Development Manufacturing Organization, recently annou...